Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Imugene LtdTelephone
N/A
Address
Suite 12.01, Level 12 4-6 Bligh Street Sydney, New South Wales (NSW) 2000
Description
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. Its products include b-cell peptide cancer vaccines, arginine modulators, and mimotopes. The company was founded on May 30, 1986 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.12
Trade Value (12mth)
AU$304,220.00
1 week
-6.82%
1 month
5.13%
YTD
5.13%
1 year
-62.73%
All time high
0.63
EPS 3 yr Growth
427.50%
EBITDA Margin
N/A
Operating Cashflow
-$97m
Free Cash Flow Return
-63.00%
ROIC
-96.90%
Interest Coverage
-282.40
Quick Ratio
3.90
Shares on Issue (Fully Dilluted)
7274m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
6.16
Date | Announcements |
---|---|
10 January 25 |
Imugene Receives $11.7m R&D Tax Refund
×
Imugene Receives $11.7m R&D Tax Refund |
10 January 25 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
03 January 25 |
First Australian Patient Dosed in Phase 1b azer-cel Trial
×
First Australian Patient Dosed in Phase 1b azer-cel Trial |
24 December 24 |
Proposed issue of securities - IMU
×
Proposed issue of securities - IMU |
23 December 24 |
Issuance of Convertible Notes & Warrants for up to $46m
×
Issuance of Convertible Notes & Warrants for up to $46m |
23 December 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
20 December 24 |
Azer-cel Accepted for Presentation at ASTCT Tandem Meetings
×
Azer-cel Accepted for Presentation at ASTCT Tandem Meetings |
19 December 24 |
Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
×
Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund |
20 November 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
20 November 24 |
Updated Appendix 3Z
×
Updated Appendix 3Z |
15 November 24 |
Director Resignation
×
Director Resignation |
14 November 24 |
Imugene AGM Presentation
×
Imugene AGM Presentation |
14 November 24 |
Imugene 2024 AGM Results
×
Imugene 2024 AGM Results |
11 November 24 |
onCARlytics Trial Doses First Patient in IT Combination Arm
×
onCARlytics Trial Doses First Patient in IT Combination Arm |
08 November 24 |
Imugene Opens First Australian Site for azer-cel Trial
×
Imugene Opens First Australian Site for azer-cel Trial |
05 November 24 |
Complete Response in MAST Study Maintained Over Two Years
×
Complete Response in MAST Study Maintained Over Two Years |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
14 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
14 October 24 |
Application for quotation of securities - IMU
×
Application for quotation of securities - IMU |
14 October 24 |
Notification of cessation of securities - IMU
×
Notification of cessation of securities - IMU |
14 October 24 |
Notification regarding unquoted securities - IMU
×
Notification regarding unquoted securities - IMU |
30 September 24 |
Change of Director's Interest Notice - PH
×
Change of Director's Interest Notice - PH |
18 September 24 |
Imugene Receives Orphan Drug Designation for VAXINIA
×
Imugene Receives Orphan Drug Designation for VAXINIA |
11 September 24 |
Appendix 2A
×
Appendix 2A |
09 September 24 |
Imugene Corporate Presentation
×
Imugene Corporate Presentation |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.